Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 4;14(19):4839.
doi: 10.3390/cancers14194839.

Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort

Hyunji Jo  1   2 , Seri Park  3 , Hye Ryeon Kim  1 , Hongsik Kim  1 , Joohyun Hong  1 , Jeong Eon Lee  4 , Jonghan Yu  4 , Byung Joo Chae  4 , Se Kyung Lee  4 , Jai Min Ryu  4 , Soo-Young Oh  5 , Suk Joo Choi  5 , Ji-Yeon Kim  1 , Jin Seok Ahn  1 , Young-Hyuck Im  1 , Eun Mi Nam  2 , Seok Jin Nam  4 , Yeon Hee Park  1   3
Affiliations

Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort

Hyunji Jo et al. Cancers (Basel). .

Abstract

Background: Given that peak age of breast cancer (BC) is younger in Asians than in Western populations, relatively higher prevalence of pregnancy-associated breast cancer (PABC) has been reported. This study aimed to analyze the characteristics and clinical outcomes of PABC in Korea. Methods: We defined PABC as BC diagnosed during pregnancy or in the first postpartum year. We compared the clinicopathological characteristics and BC outcomes between patients with PABC and non-PABC patients in the prospective YBC cohort from Samsung Medical Center. Results: In total, 1492 patients were initially enrolled, and 1364 patients were included, of which 93 had PABC (6.8%). The median age of patients with PABC was 34 years. Hormone receptor expression was lower (64.6% vs 74.6%) and frequency of HER2 overexpression was higher (26.9% vs 17.6%) in patients with PABC than in non-PABC patients. The 5-year overall survival (OS) rates were 83.2% and 93.4% in patients with PABC and non-PABC patients, respectively (p < 0.001). The 5-year disease-free survival (DFS) rates were 72.2% and 83.8% in PABC and non-PABC patients. Conclusion: Compared to non-PABC patients, patients with PABC had poorer OS and DFS in this prospective cohort. Exploratory biomarker analysis for PABC is warranted.

Keywords: breast cancer; pregnancy; prospective cohort.

PubMed Disclaimer

Conflict of interest statement

Y.H.P. has served a consultancy or advisory board member for AstraZeneca, Pfizer, Roche, Novartis, and Merck and received research funding from AstraZeneca, Pfizer, Roche, and Merck. All other authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Swimmer plot of patients diagnosed with breast cancer during pregnancy (n = 28).
Figure 2
Figure 2
Kaplan-Meier curves of survival of the YBC cohort. (A) Disease-free survival. (B) Overall survival. PABC, pregnancy-associated breast cancer.
See this image and copyright information in PMC

References

    1. Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int. J. Cancer. 2021;149:778–789. doi: 10.1002/ijc.33588. - DOI - PubMed
    1. Kang S.Y., Kim Y.S., Kim Z., Kim H.Y., Kim H.J., Park S., Bae S.Y., Yoon K.H., Lee S.B., Lee S.K., et al. Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry. J. Breast Cancer. 2020;23:115–128. doi: 10.4048/jbc.2020.23.e24. - DOI - PMC - PubMed
    1. Lin C.-H., Yap Y.S., Lee K.-H., Im S.-A., Naito Y., Yeo W., Ueno T., Kwong A., Li H., Huang S.-M., et al. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. J. Natl. Cancer Inst. 2019;111:1298–1306. doi: 10.1093/jnci/djz090. - DOI - PMC - PubMed
    1. Yap Y.-S., Lu Y.-S., Tamura K., Lee J.E., Ko E.Y., Park Y.H., Cao A.-Y., Lin C.-H., Toi M., Wu J. Insights into breast cancer in the east vs the west: A review. JAMA Oncol. 2019;5:1489–1496. doi: 10.1001/jamaoncol.2019.0620. - DOI - PubMed
    1. Paluch-Shimon S., Cardoso F., Partridge A.H., Abulkhair O., Azim H.A., Jr., Bianchi-Micheli G., Cardoso M.-J., Curigliano G., Gelmon K.A., Harbeck N. ESO–ESMO 4th International consensus guidelines for breast cancer in young women (BCY4) Ann. Oncol. 2020;31:674–696. doi: 10.1016/j.annonc.2020.03.284. - DOI - PubMed